Methods for targeted insertion of DNA in genes
Methods and compositions for modifying the coding sequence of endogenous genes using rare-cutting endonucleases and transposases. The methods and compositions described herein can be used to modify the coding sequence of endogenous genes.
1. A transgene comprising from 5′ to 3′ orientation:
a first splice acceptor, a first coding sequence, a first terminator, a second terminator reverse complement, a second coding sequence reverse complement, and a second splice acceptor reverse complement, wherein the first coding sequence is operably linked to the first splice acceptor and first terminator, and the second coding sequence is operably linked to the second splice acceptor and second terminator,
wherein the first terminator is selected from an SV40 poly(A) or BGH poly(A),
wherein the first and second coding sequences differ in nucleic acid sequence but encode the same amino acids, wherein said amino acids encoded by the first and second coding sequences correspond to amino acids encoded by an endogenous Factor IX gene, and
wherein the transgene is equal to or less than 4.7 kb.
2. The transgene of claim 1 , wherein the second terminator is selected from an SV40 poly(A) or BGH poly(A).
3. The transgene of claim 2 , wherein the amino acids encoded by the first and second coding sequences have at least 80% sequence identity to the amino acids encoded by the endogenous Factor IX gene, wherein the percent sequence identity is calculated by matching amino acids encoded by the first and second coding sequence with amino acids encoded by an endogenous Factor IX gene and dividing the number of matches by the length of the amino acids encoded by the first and second coding sequence, followed by multiplying the resulting value by 100.
4. The transgene of claim 3 , wherein the amino acids encoded by the first and second coding sequences have about 98% sequence identity to the amino acids encoded by an endogenous Factor IX gene.
5. The transgene of claim 3 , wherein the amino acids encoded by the first and second coding sequences have about 99% sequence identity to the amino acids encoded by an endogenous Factor IX gene.
6. The transgene of claim 3 , wherein the transgene is harbored on a viral vector.
7. The transgene of claim 6 , wherein the viral vector is selected from the group consisting of an adenovirus vector, an adeno-associated virus vector, and a lentivirus vector.
8. The method of claim 7 , wherein the viral vector is an adeno-associated viral vector.
9. The transgene of claim 8 , wherein the viral vector is incorporated into a viral particle.
10. The transgene of claim 9 , wherein the transgene does not comprise homology arms.
11. The transgene of claim 10 , wherein the first splice acceptor comprises a splice acceptor sequence from an intron of the endogenous Factor IX gene.
12. An adeno-associated viral vector comprising:
(i) a transgene comprising from 5′ to 3′ orientation a first splice acceptor, a first coding sequence, a first terminator, a second terminator reverse complement, a second coding sequence reverse complement, and a second splice acceptor reverse complement, wherein the first coding sequence is operably linked to the first splice acceptor and first terminator, and the second coding sequence is operably linked to the second splice acceptor and second terminator,
wherein the first and second coding sequences differ in nucleic acid sequence but encode the same amino acids, wherein said amino acids encoded by the first and second coding sequences correspond to amino acids encoded by an endogenous gene, and
wherein the transgene is equal to or less than 4.7 kb; and
(ii) adeno-associated virus inverted terminal repeats flanking the transgene.
13. The adeno-associated viral vector of claim 12 , wherein the endogenous gene is Factor IX.
14. The adeno-associated viral vector of claim 13 , wherein the first and second coding sequences encode amino acids having at least 80% sequence identity to the amino acids encoded by the endogenous Factor IX gene, wherein the percent sequence identity is calculated by matching amino acids encoded by the first and second coding sequence with amino acids encoded by an endogenous Factor IX gene and dividing the number of matches by the length of the amino acids encoded by the first and second coding sequence, followed by multiplying the resulting value by 100.
15. The adeno-associated viral vector of claim 14 , wherein the amino acids encoded by the first and second coding sequences have about 98% sequence identity to the amino acids encoded by an endogenous Factor IX gene.
16. The adeno-associated viral vector of claim 14 , wherein the amino acids encoded by the first and second coding sequences have about 99% sequence identity to the amino acids encoded by an endogenous Factor IX gene.
17. The adeno-associated viral vector of claim 13 , wherein the first terminator is selected from an SV40 poly(A) or BGH poly(A).
18. The adeno-associated viral vector of claim 17 , wherein the second terminator is selected from an SV40 poly(A) or BGH poly(A).
19. The adeno-associated viral vector of claim 18 , wherein the viral vector is incorporated into a viral particle.
20. The adeno-associated viral vector of claim 18 , wherein the transgene does not comprise homology arms.
21. The adeno-associated viral vector of claim 20 , wherein the first splice acceptor comprises splice acceptor sequence from an intron of the endogenous Factor IX gene.
22. The adeno-associated viral vector of claim 20 , wherein the first terminator is SV40 poly(A) and the second terminator is BGH poly(A).